Corcept Therapeutics Inc (CORT): Cash & Equivalents
$120.50M
As of 2025-12-31
$111.04M
As of 2026-06-30
+22.0%
3-year compound annual growth
+9.6%
5-year compound annual growth
+11.5%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $120.50M | -5.6% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $127.67M | -5.8% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $135.55M | +104.4% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $66.33M | -14.5% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $77.62M | +1.9% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $76.19M | +143.7% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $31.27M | -24.9% | 2021-02-23, Balance as of period end |
| 2018-12-31 | $41.62M | +34.0% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $31.06M | -39.7% | 2020-02-24, Balance as of period end |
| 2016-12-31 | $51.54M | +27.5% | 2019-02-26, Balance as of period end |
| 2015-12-31 | $40.44M | +66.8% | 2018-02-28, Balance as of period end |
| 2014-12-31 | $24.25M | -55.8% | 2017-03-06, Balance as of period end |
| 2013-12-31 | $54.88M | -41.0% | 2016-03-10, Balance as of period end |
| 2012-12-31 | $93.03M | +134.7% | 2015-03-13, Balance as of period end |
| 2011-12-31 | $39.63M | +61.3% | 2014-03-14, Balance as of period end |
| 2010-12-31 | $24.58M | +3.0% | 2013-03-15, Balance as of period end |
| 2009-12-31 | $23.87M | +62.2% | 2012-03-13, Balance as of period end |
| 2008-12-31 | $14.72M | n/a | 2012-03-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $120.50M | -5.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $205.40M | +106.4% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $231.25M | +227.7% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $158.54M | -42.7% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $170.18M | +12.2% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $128.45M | +85.3% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $421.00M | +142.0% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $752.50M | +66.1% |
Compare CORT, EBS, COLL, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗